ライフサイエンスコーパス: interleukin-5

1 ment was likely due to systemic reduction in interleukin 5.

2 correlated with levels of tryptase, EDN, and interleukin-5.

3 asma eosinophil-derived neurotoxin (EDN) and interleukin-5.

4 roduced interferon-gamma and lower levels of interleukin-5.

5 ing mice with neutralizing antiserum against interleukin-5.

6 umab, a monoclonal antibody directed against interleukin-5.

7 ukin-2, interferon-gamma, interleukin-4, and interleukin-5.

8 ryptase in sputum and lower plasma levels of interleukin-5.

9 duction of granzyme B, interferon-gamma, and interleukin-5.

10 a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in e

11 a humanised monoclonal antibody that targets interleukin-5, a key cytokine in type 2 inflammation, is

12 erapy, bolstering eosinophils by intravenous interleukin-5 administration promotes the efficacy of ra

13 markers associated with response to the anti-interleukin 5 agent, mepolizumab, and to the anti-immuno

14 e the lack of production of the Th2 cytokine interleukin 5 and the chemokine eotaxin, which are cruci

15 ith airway eosinophils and concentrations of interleukin-5 and -13.

16 uch as increased expression of IgA-promoting interleukin-5 and anti-inflammatory transforming growth

17 This review highlights current literature on interleukin-5 and eosinophil production.

18 E, IgG, IgG1, and IgG2a levels as well as in interleukin-5 and interferon-gamma levels in BALF and in

19 terized by elevated antibody titers and high interleukin-5 and interleukin-10 cytokine levels; import

20 esize extremely low levels of interleukin-4, interleukin-5 and interleukin-10, but normal amounts of

21 n-gamma in the type-1 response, and enhanced interleukin-5 and interleukin-13 in the type-2 response.

22 ce of adaptive T-cell immunity that involves interleukin-5 and interleukin-13-induced esophageal epit

23 pment of eosinophilic esophagitis, including interleukin-5 and interleukin-13.

24 tudy found significantly increased levels of interleukin-5 and interleukin-8, critical cytokines of t

25 s, such as humanised antibodies against IgE, interleukin 5, and interleukin 13, offer hope to improve

26 molecular signaling, physiologic sources of interleukin-5, and interactions between interleukin-5, e

27 Mig, as well as variable induction of B7.1, interleukin-5, and interferon gamma expression was noted

28 vealed induction of IP-10, Mig, B7.1 (CD80), interleukin-5, and interferon gamma in selected patients

29 and in vivo, with more robust interleukin-4, interleukin-5, and interleukin-13 production than their

30 , RSV F(51-66)-specific CD4 T cells secreted interleukin-5, and mice developed pulmonary eosinophilia

31 ntiation and gene expression, independent of interleukin-5, and regardless of inclusion of cytokines

32 -D content, gamma interferon, interleukin-4, interleukin-5, and tumor necrosis factor alpha in BAL fl

33 rferon-gamma-producing) and type 2 T helper (interleukin-5- and -10-producing) peripheral blood lymph

34 ron-gamma, and interleukin-6, with increased interleukin-5] and decreased CNS white matter inflammati

35 ies examining cytokine blockers such as anti-interleukin-5, anti-interleukin-4Ralpha, and anti-interl

36 ministration's recommendation to use an anti-interleukin-5 antibody for the treatment of severe eosin

37 es targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 as

38 yte-macrophage colony-stimulating factor and interleukin 5, Bax spontaneously underwent activation an

39 ing biological drug engineered with enhanced interleukin-5 binding affinity, high potency, and an ext

40 tion of interferon-gamma, interleukin-2, and interleukin-5, but up-regulates transforming growth fact

41 eral blood of healthy donors, incubated with interleukin 5, cocultured with fibroblasts, and analyzed

42 patient who did not respond had raised serum interleukin-5 concentrations.

43 s with hypereosinophilic syndrome and normal interleukin-5 concentrations.

44 interferon-gamma) and Th2 (interleukin-4 and interleukin-5) cytokines.

45 of fibroblasts in soft agar and relieves the interleukin-5 dependence of a pre-B-cell line.

46 hybridization analysis, mT4 is expressed in interleukin-5-dependent mouse eosinophils, as well as in

47 ked down-regulation of the hSP-C promoter is interleukin-5-dependent, implying a critical role for eo

48 s of interleukin-5, and interactions between interleukin-5, eosinophils, and the bone marrow microenv

49 This mRNA was expressed at high levels in interleukin 5-exposed eosinophils, elicited peritoneal m

50 T-helper type 1 (Th1) cells but increases in interleukin 5-expressing Th2 cells and eosinophils in pe

51 T-helper type 1 (Th1) cells but increases in interleukin 5-expressing Th2 cells and eosinophils in pe

52 ated the infection depending on the level of interleukin-5 expression.

53 show that transcriptional repression of the Interleukin-5 gene involves recruitment of GR to a DNA r

54 cal keratitis in control C57Bl/6 mice and in interleukin-5 gene knockout (IL-5(-/-)) mice.

55 orm infection, albendazole treatment reduced interleukin-5 (geometric mean ratio 0.50, 95% CI 0.30-0.

56 Interleukin-5 has been identified as a major regulator o

57 persistent airway eosinophilia, blockade of interleukin-5 has significant steroid-sparing effects an

58 lonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbat

59 ntibodies targeted to interleukin 4alpha and interleukin 5 have shown substantial benefit in patients

60 The high-affinity receptor for human interleukin-5 (hIL-5) is composed of alpha and beta subu

61 with monoclonal antibodies directed against interleukin-5, IgE or CD4 yielded results that were crit

62 inophil survival-promoting cytokines such as interleukin 5 (IL-5) and granulocyte-macrophage colony-s

63 ed DCs were associated with higher levels of interleukin 5 (IL-5) and IL-13 and a lower level of CXCL

64 cells (Th2 cells) are the primary source of interleukin 5 (IL-5) and IL-13 during type 2 (allergic)

65 an enhanced T helper type-2 (Th2) [increased interleukin 5 (IL-5) and interleukin 13 (IL-13)] and T r

66 In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vacci

67 y suggests a potentially protective role for interleukin 5 (IL-5) in sepsis; however, the loss of eos

68 Culture of eosinophils with interleukin 5 (IL-5) leads to a two- to fourfold increas

69 The ligand-binding alpha-chain of the human interleukin 5 (IL-5) receptor was expressed in its solub

70 Peripheral blood mononuclear cell interleukin 5 (IL-5) responses to F-OvAg and Smf decline

71 ex vivo differentiation assay, we found that interleukin 5 (IL-5) supports the generation of Ly6G(+)

72 of single-chain and monomeric forms of human interleukin 5 (IL-5) was performed to investigate mechan

73 The normally dimeric human interleukin 5 (IL-5) was re-engineered into two monomeri

74 ncept, we developed a 5-plex assay measuring interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin

75 n and immunoglobulin production by secreting interleukin 5 (IL-5).

76 ated by the central eosinophil growth factor interleukin 5 (IL-5).

77 d mRNA expression of the TH2-type cytokines, interleukin-5 (IL-5) and granulocyte-macrophage colony-s

78 s (n = 33) had higher levels of constitutive interleukin-5 (IL-5) and IL-10, increased microfilarial

79 t a relatively steroid-insensitive source of interleukin-5 (IL-5) and IL-13 and are considered critic

80 2 ILCs (ILC2s) produce type 2 cytokines like interleukin-5 (IL-5) and IL-13 and require GATA3, and gr

81 xpression of mRNA for the Th2-type cytokines interleukin-5 (IL-5) and IL-13 as well as some increase

82 g epithelial cells inducing the elevation of interleukin-5 (IL-5) and IL-13 from natural helper (NH)

83 increased amounts of inflammatory cytokines interleukin-5 (IL-5) and IL-13 in lung lavage fluid, dec

84 leads to an increase in the Type 2 cytokines interleukin-5 (IL-5) and IL-13; however, the effect of s

85 s of PP CD4(+) T helper (Th) cells secreting interleukin-5 (IL-5) and IL-6 and splenic CD4(+) Th cell

86 Surprisingly, GALT DCs, together with interleukin-5 (IL-5) and IL-6, also provided a milieu fo

87 ml), and culture supernates were assayed for interleukin-5 (IL-5) and interferon-gamma by enzyme-link

88 in the bronchoalveolar lavage fluid (BALF); interleukin-5 (IL-5) and leukotriene concentrations in B

89 ent killer cell activity, elevated levels of interleukin-5 (IL-5) and percentages of eosinophils in t

90 Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 day

91 Observations that monoclonal antibodies to interleukin-5 (IL-5) are well tolerated appear unsurpris

92 We also identify interleukin-5 (IL-5) as a novel inducer of killer B cell

93 ents with severe asthma, treatment with anti-interleukin-5 (IL-5) biologics can lead to a reduction i

94 We show that interleukin-5 (IL-5) deficiency profoundly impairs VAT e

95 Interleukin-5 (IL-5) drives the terminal differentiation

96 To investigate the role of interleukin-5 (IL-5) during Toxoplasma gondii infection,

97 Gamma interferon (IFN-gamma) and interleukin-5 (IL-5) enzyme-linked immunospot (ELISPOT)

98 n of the airways and increased production of interleukin-5 (IL-5) in cultures of peribronchial lymph

99 Our studies examined the role of interleukin-5 (IL-5) in helminth-induced pulmonary eosin

100 P-D have reduced eosinophil infiltration and interleukin-5 (IL-5) in lung lavage fluid.

101 hil-active cytokines showed unique patterns: interleukin-5 (IL-5) increased in the antigen segment on

102 Interleukin-5 (IL-5) is a hematopoietic differentiation

103 ition of eosinophil apoptosis by exposure to interleukin-5 (IL-5) is associated with the development

104 Interleukin-5 (IL-5) is essential for the formation of e

105 Interleukin-5 (IL-5) is the key cytokine for eosinophils

106 Here, we used interleukin-5 (IL-5) knockout (KO) mice to determine whe

107 Response was not predicted by serum interleukin-5 (IL-5) levels or presence of the FIP1L1/PD

108 netic interactions of a humanized anti-human interleukin-5 (IL-5) monoclonal antibody (SCH 55700) wit

109 p of patients with HES show T-cell-dependent interleukin-5 (IL-5) overexpression, we determined if ex

110 Within this response, interleukin-5 (IL-5) plays a central role in eosinophil

111 Interleukin-5 (IL-5) plays a central role in the differe

112 Preliminary data showing enhanced interleukin-5 (IL-5) production by T cells from infected

113 primed T cells and CD4+ T cells to increase interleukin-5 (IL-5) production.

114 Interleukin-5 (IL-5) regulates the growth and function o

115 Interleukin-5 (IL-5) specifically induces the differenti

116 transcript levels rapidly increase following interleukin-5 (IL-5) stimulation of CD34(+) hematopoieti

117 of phagocytizing bacteria, neutralization of interleukin-5 (IL-5) to inhibit eosinophil recruitment l

118 4(+) gamma interferon (IFN-gamma)(+), CD4(+) interleukin-5 (IL-5)(+), and CD4(+) IL-17A(+) phenotypes

119 (GM-CSF) and the single structural domain of interleukin-5 (IL-5), all of which share a common recept

120 suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation,

121 nts using a humanised monoclonal antibody to interleukin-5 (IL-5), and animal studies involving speci

122 of CII-specific interferon-gamma (IFNgamma), interleukin-5 (IL-5), and IL-10 was determined by enzyme

123 nhibited the production of gamma interferon, interleukin-5 (IL-5), and IL-12.

124 interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), and tumor necrosis factor alpha (T

125 ession of three eosinophil chemoattractants: interleukin-5 (IL-5), eotaxin, and regulated on activato

126 Antigen-specific interleukin-5 (IL-5), gamma interferon (IFN-gamma), and

127 However, elevated levels of interleukin-5 (IL-5), generated by transgenic or pharmac

128 alysis of tumour necrosis factor (TNF) beta, interleukin-5 (IL-5), IL-10, Forkhead box P3 (FOXP3) and

129 increased levels of eosinophils, mast cells, interleukin-5 (IL-5), IL-13, gamma interferon, immunoglo

130 type 2 (anti-helminths) effectors, including interleukin-5 (IL-5), IL-13, immunoglobulin E and eosino

131 The eosinophil-active cytokines interleukin-5 (IL-5), IL-6, and IL-10 were strikingly el

132 at regions of LSA-1 stimulated production of interleukin-5 (IL-5), interleukin-10 (IL-10), gamma inte

133 To delineate a role for interleukin-5 (IL-5), interleukin-4 (IL-4), and interfer

134 reatment with the rat anti-mouse antibody to interleukin-5 (IL-5), TRFK-5 (10-300 microg, intraperito

135 Interleukin-5 (IL-5), which is produced by CD4(+) T help

136 During schistosomiasis, interleukin-5 (IL-5)-dependent eosinophil responses have

137 nown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia

138 levels of malaria-specific IgG1 antibody and interleukin-5 (IL-5)-producing T cells.

139 s, we analyzed eosinophil differentiation in interleukin-5 (IL-5)-stimulated umbilical cord stem cell

140 is, and activation is primarily regulated by interleukin-5 (IL-5).

141 onstrated with parathyroid hormone (PTH) and interleukin-5 (IL-5).

142 t of T cells in the airway and generation of interleukin-5 (IL-5).

143 gamma [IFN-gamma]) as well as selective Th2 (interleukin-5 [IL-5] and IL-6) cytokine responses than d

144 in T cell cytokine levels (interferon-gamma, interleukin-5 [IL-5], IL-10, IL-17) were detected after

145 , vascular endothelial growth factor (VEGF), interleukin 5 (IL5), CCL17, CCL22, CXCL9 and CXCL10.

146 s, interleukin 3 (Il3), interleukin 4 (Il4), interleukin 5 (Il5), interleukin 13 (Il13), and granuloc

147 ial for high affinity interaction with human interleukin 5 (IL5).

148 previously demonstrated that AF17121 mimics Interleukin-5 (IL5) by binding in a region of IL5Ralpha

149 21 is a library-derived antagonist for human interleukin-5 (IL5) receptor alpha (IL5Ralpha) and inhib

150 sinophils around the airway, lower levels of interleukin 5 in the lung, and reduced serum levels of i

151 ponses were associated with the detection of interleukin 5 in the serum.

152 IgE in serum, and increased eosinophilia and interleukin-5 in bronchoalveolar lavage (BAL) compared t

153 This was characterized by increased interleukin-5 in lung supernatants and an increase in G-

154 and -13 in antigen-induced dysmotility, and interleukin-5 in the pathogenesis of mucosal eosinophili

155 st clones secreted gamma interferon, but not interleukin-5, in response to antigen.

156 nregulation of Th2 cytokines (interleukin 4, interleukin 5, interleukin 10, interleukin 13).

157 ll responsive (as measured by proliferation, interleukin-5, interleukin-10, interferon-gamma, and gra

158 + Cort) levels of two Th-2 cytokines (i.e., interleukin-5, interleukin-13) and one Th-1 cytokine (i.

159 ecreased leukocytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and

160 This analysis indicated that interleukin-5, interleukin-6, and granulocyte-colony sti

161 ssayed for interleukin-1beta, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin

162 rleukin-1beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-9, interleukin

163 interleukin-2 receptor-alpha, interleukin-4, interleukin-5, interleukin-7, interleukin-13, interleuki

164 Interleukin 5 is recently gaining a lot of attention as

165 Interleukin-5 is a Th2 homodimeric cytokine involved in

166 th mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exace

167 Serum interleukin 5 levels and eosinophil activation, as asses

168 a significant reduction in interleukin-4 and interleukin-5 levels and a significant increase in inter

169 e eosinophil counts, lung interleukin-13 and interleukin-5 levels, and airway hyperreactivity.

170 vels (P<.06) and a tendency toward increased interleukin-5 levels, compared with helminth-free patien

171 all 4 responding patients had elevated serum interleukin-5 levels.

172 ng of the interleukin 5 receptor rather than interleukin 5 ligand.

173 controls, levels of the chemotactic factors interleukin-5, macrophage inflammatory protein-1 alpha,

174 ilic syndrome, the therapeutic niche of anti-interleukin-5 (mepolizumab) and anti-CD52 (alemtuzumab)

175 Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinoph

176 In this study, we report that anti-interleukin-5 monoclonal antibody (TRFK-5) treatment can

177 Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on the

178 These results demonstrate that anti-interleukin-5 monoclonal antibody treatment can effectiv

179 valuating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patie

180 Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinop

181 tle phenotypes, whereas other genes, such as interleukin-5 or osteoprotegerin, were initially identif

182 actor beta, gamma interferon, interleukin-4, interleukin-5, or interleukin-6 for all mouse strains.

183 Interleukin-5 plays a pivotal role in the regulation of

184 are the major source of interferon-gamma and interleukin-5 produced in response to alloantigen.

185 n-atopic donors suppressed proliferation and interleukin 5 production by their own allergen-stimulate

186 HPV antigen--specific interferon--gamma and interleukin-5 production were measured from PBMC culture

187 ffect on interferon-gamma production than on interleukin-5 production.

188 phils stimulated with IgA immune complex and interleukin 5 promote neurite extension of the PC-12 phe

189 ty also showed significant correlations with interleukin-5 (r = 0.66, p = 0.002), transforming growth

190 in patients who died, with a serum G-CSF to interleukin 5 ratio of >100 at admission being the most

191 Human interleukin 5 receptor alpha (IL5Ralpha) comprises three

192 efficacy and safety of benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody that de

193 Benralizumab is a humanised, anti-interleukin 5 receptor alpha monoclonal antibody that di

194 ls per muL, possibly due to targeting of the interleukin 5 receptor rather than interleukin 5 ligand.

195 BCR) or the mast cell Fcepsilon receptor, or interleukin 5 receptor stimulation each induced rapid ph

196 contrast, introduction and activation of the interleukin-5 receptor (IL-5R) or of the granulocyte-mac

197 lular domain of the alpha chain of the human interleukin-5 receptor (IL-5Ralpha), but share no primar

198 vels of B-cell maturation antigen (BCMA) and interleukin-5 receptor alpha (IL5RA) in plasma.

199 E) is a library-derived antagonist for human Interleukin-5 receptor alpha (IL5Ralpha).

200 ically important gene products (for example, interleukin-5 receptor alpha chain, IL-5R alpha).

201 phage surface and binding of scIL-5 phage to interleukin-5 receptor alpha chain.

202 Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor alpha monoclonal antibody that ha

203 ralizumab is a humanised, afucosylated, anti-interleukin-5 receptor alpha monoclonal antibody that in

204 Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, deplet

205 Benralizumab is an eosinophil-depleting anti-interleukin-5 receptor alpha monoclonal antibody.

206 benralizumab, a monoclonal antibody against interleukin-5 receptor alpha that depletes eosinophils b

207 enralizumab is a monoclonal antibody against interleukin-5 receptor alpha, which is expressed on huma

208 Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclon

209 affinity changes mediated by IgE receptor or interleukin-5 receptor persist longer.

210 dy directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the in

211 Expression of the interleukin-5 receptor-alpha (IL-5Ralpha) chain is thoug

212 utive and alternative splicing of the murine interleukin-5 receptor-alpha (IL-5Ralpha) chain pre-mRNA

213 n (betac), shared with the interleukin-3 and interleukin-5 receptors.

214 production are enhanced by interleukin-4 and interleukin-5, respectively, these findings suggest that

215 nduction of PA-specific gamma interferon and interleukin 5 responses was observed in splenocytes.

216 Interleukin-5 responses were not different among CD, UC,

217 1 type (ie, strong interferon-gamma and weak interleukin-5 responses).

218 eatment with TRFK5, a monoclonal antibody to interleukin-5, resulted in a 76% decrease in eosinophil

219 n the presence of 10 pg/ml human recombinant interleukin-5 (rhIL-5) and activated with formyl-met-leu

220 nctional phage display of single chain human interleukin-5 (scIL-5) and its use for receptor-binding

221 Dual asymmetric mutagenesis of single-chain interleukin 5 (scIL5) was used to obtain evidence that t

222 Although their Her-2-specific IgG1 and interleukin-5-secreting T cells increased, the levels of

223 Immunization with antigen and AlOH induced interleukin-5-secreting, antigen-specific T cells, and i

224 ody (mAb) inhibited eosinophil infiltration, interleukin 5 secretion, and IgE production.

225 daily; four male patients with normal serum interleukin 5 showed complete haematological responses;

226 ee genes, interleukin-4, interleukin-13, and interleukin-5, spread over 120 kilobases.

227 e sequencing of a cDNA library prepared from interleukin-5-stimulated umbilical cord precursor cells

228 te-macrophage colony-stimulating factor, and interleukin-5, suggesting a role for the beta common (be

229 c therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing i

230 lonal antibody that binds to and neutralizes interleukin-5, the major cytokine involved in eosinophil

231 tiple other medical treatments for EoE: anti-interleukin-5 therapy, anti-interleukin-13 therapy, anti

232 en-specific gamma interferon (IFN-gamma) and interleukin 5 to levels comparable to those achieved wit

233 We hypothesized that J558L HI, an interleukin 5-transfected murine plasmacytoma that is in

234 Moreover, larvae were killed in naive interleukin-5 transgenic mice, and the killing coincided

235 In vivo, interleukin-5 transgenic mice, which have profound eosin

236 evented by anti-very late antigen-4 and anti-interleukin-5 treatments, which blocked airway eosinophi

237 The cytokine interleukin-5 was chemokinetic for bone marrow eosinophi

238 analysis with gene-targeted mice showed that interleukin-5 was required for esophageal eosinophilia a

239 ere not degranulated and increased levels of interleukin-5 were measured in bronchoalveolar lavage an

240 locyte colony-stimulating factor, as well as interleukin 5, which may be responsible for the decrease

241 mab, a humanized monoclonal antibody against interleukin-5, which was administered as either a 75-mg

242 strains of mice produced only low levels of interleukin-5, with no detectable level of interleukin-4

243 ux and shifted cytokine production away from interleukin-5 without reducing the resistance to viral r

244 Wild type human (h) interleukin 5 (wt IL5) is composed of two identical pept